Berger Montague Investigates Class Action for LifeMD Investors Amidst Financial Scandal
On August 28, 2025, the national law firm Berger Montague PC announced the initiation of a class action lawsuit against LifeMD, Inc., a telehealth company traded under NASDAQ symbol LFMD. This legal action has been initiated on behalf of investors who purchased shares of LifeMD during a specified period, which spans from May 7, 2025, to August 5, 2025. As claims mount, the firm is urging those affected to act swiftly to protect their interests and possibly assume the role of lead plaintiff in this significant case.
LifeMD is well-known for offering direct-to-consumer healthcare services and virtual pharmacy solutions, providing treatments across various health sectors including men’s health, obesity interventions, and chronic condition management. However, the lawsuit brings to light troubling allegations regarding the company’s financial practices. The complaint asserts that LifeMD significantly overstated its competitive standing and engaged in reckless business conduct, particularly regarding its updated projections for 2025.
Specifically, claims suggest that LifeMD failed to adequately account for escalated customer acquisition costs related to both its RexMD telehealth segment and its obesity-related drug offerings, which include well-known medications such as Wegovy and Zepbound. The fallout from these revelations was severe—when the truth about the company's financial situation became public, investors witnessed a staggering 44% drop in share value in a single trading session, signaling mounting concerns over the viability of LifeMD’s current business model.
Investors who are concerned about their stakes in LifeMD can act before the looming deadline of October 27, 2025, which is when they must file their motion to be appointed as a lead plaintiff representative. Those interested in understanding their rights or joining the lawsuit can contact either Andrew Abramowitz or Caitlin Adorni at Berger Montague using the provided details in the press release.
Founded in 1970, Berger Montague has established itself as a pioneering firm in securities class action litigation, with a track record of representing investors both institutional and individual in courtrooms across the United States. With offices located in key cities such as Philadelphia, Minneapolis, and San Francisco, the firm has successfully navigated complex legal landscapes to advocate for the rights of investors for over five decades.
For those wishing to explore their legal options or have questions regarding this lawsuit, reaching out to Berger Montague is a crucial first step. The firm's expertise can assist in understanding the intricacies surrounding securities fraud and investor rights, ensuring that victims of potential corporate misconduct can take informed actions to safeguard their financial investments.
LifeMD is well-known for offering direct-to-consumer healthcare services and virtual pharmacy solutions, providing treatments across various health sectors including men’s health, obesity interventions, and chronic condition management. However, the lawsuit brings to light troubling allegations regarding the company’s financial practices. The complaint asserts that LifeMD significantly overstated its competitive standing and engaged in reckless business conduct, particularly regarding its updated projections for 2025.
Specifically, claims suggest that LifeMD failed to adequately account for escalated customer acquisition costs related to both its RexMD telehealth segment and its obesity-related drug offerings, which include well-known medications such as Wegovy and Zepbound. The fallout from these revelations was severe—when the truth about the company's financial situation became public, investors witnessed a staggering 44% drop in share value in a single trading session, signaling mounting concerns over the viability of LifeMD’s current business model.
Investors who are concerned about their stakes in LifeMD can act before the looming deadline of October 27, 2025, which is when they must file their motion to be appointed as a lead plaintiff representative. Those interested in understanding their rights or joining the lawsuit can contact either Andrew Abramowitz or Caitlin Adorni at Berger Montague using the provided details in the press release.
Founded in 1970, Berger Montague has established itself as a pioneering firm in securities class action litigation, with a track record of representing investors both institutional and individual in courtrooms across the United States. With offices located in key cities such as Philadelphia, Minneapolis, and San Francisco, the firm has successfully navigated complex legal landscapes to advocate for the rights of investors for over five decades.
For those wishing to explore their legal options or have questions regarding this lawsuit, reaching out to Berger Montague is a crucial first step. The firm's expertise can assist in understanding the intricacies surrounding securities fraud and investor rights, ensuring that victims of potential corporate misconduct can take informed actions to safeguard their financial investments.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.